A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Research Problem:
Bladder cancer is one of the major health concerns of the world. The present methods of
diagnosis are: Ultra sound, Cystoscopy, CT scan and urine cytology. All these are stressful
to the patients, particularly Cystoscopy which is commonly employed for the follow up of
Bladder cancer patients.
Research Significance:
The present study will employ a new photodynamic diagnostic procedure to quantify a certain
cancer specific biomarker called Porphyrin, which selectively binds on to the bladder cancer
tissues. In this context the present technique offer viable, very easy and reliable table top
instrumentation for diagnosis and continual monitoring of disease regression through urine.
Research Objectives:
- To quantify bladder cancer specific biomarkers such as Porphyrin using photodynamic
diagnostic procedure
- To find out whether this technique might be a new and easy tool for bladder cancer
diagnosis only by urine.
Research Methodology:
The bladder cancer patients is required to swallow a chemical called ALA (5 Amino levulinic
Acid hydrochloride), about 10mg/kg body weight which will play a role of biological
indicator. ALA gets metabolized into certain types of porphyrins which selectively bind on to
the tumor tissues (for a longer time than the normal tissues). 5ml of blood and one urine
samples will be taken before using ALA. The patient must drink water then the urine will be
collected after 4, 8 and 12 hours of taking ALA and the samples will be analyzed by
photodynamic diagnostic procedure.
Phase:
Phase 3
Details
Lead Sponsor:
Princess Al-Johara Al-Ibrahim Cancer Research Center